Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in southern China
Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in southern China
复制标题
DOI：
10.1002/ijc.26404
复制
发表时间：
2012-08-01
影响因子：
6.4
通讯作者：
Ng, H. K.
中科院分区：
文献类型：
--
作者：
Chan, Paul K. S.;Cheung, Tak-Hong;Ng, H. K.
个别人乳头瘤病毒（HPV）类型的宫颈肿瘤，特别是上皮内病变的属性，不同民族地理。疫苗成本效益评估和换型监测需要特定人群的数据。HPV检测来自2,790名中国妇女（444名浸润性宫颈癌[ICC]，772名宫颈上皮内瘤样病变[CIN] 3级，805名CIN 2和769名CIN 1）。在多种类型感染中发现的每种HPV类型的归属通过分数贡献法近似。多型感染常见，与病变严重程度呈负相关（CIN 1为54.7%，CIN 2为48.7%，CIN 3为46.2%，ICC为27.5%）。疫苗覆盖的高危型（HPV 16/18）归因于59.5%的鳞状细胞癌、78.6%的腺癌、35.9%的CIN 3、18.4%的CIN 2和7.4%的CIN 1。与世界范围相比，不同的特征是HPV 52和HPV 58的归因较高，而HPV 45的归因较低。将HPV 52和HPV 58纳入未来的疫苗将提供覆盖率的最高边际增长，鳞状细胞癌为11.7%，CIN 3为14.4%，CIN 2为22.6%，CIN 1为17.7%。中国南方HPV型别的归属与其他地区不同，在疫苗和筛查检测开发中优先考虑HPV型别时应考虑这一点。
The attribution of individual human papillomavirus (HPV) types to cervical neoplasia, especially intraepithelial lesions, varies ethnogeographically. Population-specific data are required for vaccine cost-effectiveness assessment and type replacement monitoring. HPV was detected from 2,790 Chinese women (444 invasive cervical cancers [ICC], 772 cervical intraepithelial neoplasia [CIN] grade 3, 805 CIN2 and 769 CIN1. The attribution of each HPV type found in multiple-type infections was approximated by the fractional contribution approach. Multiple-type infection was common and correlated inversely with lesion severity (54.7% for CIN1, 48.7% for CIN2, 46.2% for CIN3, 27.5% for ICC). Vaccine-covered high-risk types (HPV16/18) attributed to 59.5% of squamous cell carcinoma, 78.6% of adenocarcinoma, 35.9% of CIN3, 18.4% of CIN2 and 7.4% of CIN1. Distinct features compared to worldwide were a higher attribution of HPV52 and HPV58, and a much lower attribution of HPV45. Inclusion of HPV52 and HPV58 in future vaccines would provide the highest marginal increase in coverage with 11.7% for squamous cell carcinoma, 14.4% for CIN3, 22.6% for CIN2 and 17.7% for CIN1. The attribution of HPV types in southern China is different from elsewhere, which should be considered in prioritizing HPV types for vaccine and screening assay development.